Atavistik Bio and Pfizer have partnered to discover novel allosteric therapeutics for two undisclosed targets chosen by Pfizer. Atavistik Bio will utilize its AMPS™ platform to identify allosteric binders, and Pfizer retains the option to license the resulting programs. Financial specifics remain confidential.

This collaboration is notable because it validates Atavistik Bio’s AMPS™ platform and its ability to rapidly identify functional allosteric binding pockets, a historically difficult feat in drug discovery. For Pfizer, access to this platform offers a potential avenue to develop innovative therapies for complex targets, possibly expanding their oncology pipeline. Successfully identifying allosteric binders for these challenging targets could revolutionize treatment approaches, potentially leading to more effective and safer drugs.

The collaboration focuses on leveraging Atavistik Bio’s AMPS™ platform, integrating computational and experimental methods to find and utilize cryptic pockets in target proteins. This approach may unlock new therapeutic possibilities for previously intractable targets. While the financial terms are undisclosed, the collaboration itself and the potential licensing agreement represent significant strategic milestones for Atavistik Bio.

This collaboration signals a potential shift in the oncology landscape. The partnership’s success could expedite the development of next-generation allosteric therapies, offering new treatment options for patients and strengthening both companies’ positions in the precision oncology field. The progress of this collaboration, and Pfizer’s potential exercise of its licensing option, will be key indicators of future development in this area.

Source link: https://www.globenewswire.com/news-release/2025/01/02/3003456/0/en/Atavistik-Bio-Announces-Research-Collaboration-with-Pfizer-to-Accelerate-Discovery-of-Novel-Precision-Allosteric-Therapeutics.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.